Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Subjects With Lateral Canthal Lines
NCT04985916Phase 2Completed
- Sponsor
- Eirion Therapeutics
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ANT-1207 in lateral canthal rhytides, sponsored by Eirion Therapeutics. Primary endpoint: Investigators Global Assessment at Week 4. Started Jul 2021; status: completed.
02
Drugs
ANT-1207
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT04985916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985916.